Insmed | INSM - Gross Profit On Sales


Insmed reported $356.19M in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Cytokinetics USD 23.03M 3.84M Jun/2026
DBV Technologies USD 2.77M 33.21M Sep/2025
Gilead Sciences USD 6.8B 1.29B Jun/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Insmed USD 356.19M 99.73M Jun/2026
Novartis USD 10.07B 758M Mar/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026